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Investigation of itch in Parkinson disease
Maria A. Sondrup, MSca, Cecilie Bjergen, BSca, Anne N. Gaarskjær, BSca, Andrea Joseph, BSca,
Rikke S. Lassen, BSca, Shiran Mamedov, BSca, Maria B. Poulsen, BSca, Tessa Radovanovic, MPharma,
Cathrine S. Schacksen, BSca, Maja Thaarup, BSca, Maria S. Andersen, MScb,c, Lorenz M. Oppel, MD, PhDb,c,
Parisa Gazerani, PharmD, PhDa,d,*
Introduction: Sensory abnormalities (eg, pain) are common in Parkinson disease (PD) with a negative impact on quality of life. As
itch is less studied in PD, and pain and itch partially share sensory pathways, we designed this study to identify the occurrence and
pattern of spontaneous itch, and responsiveness to a surrogate itch model in PD.
Methods: The study protocol was approved (N-20180079) and PD patients and their best matched controls were recruited. A
questionnaire was used to collect general information on itch. Sensory alterations were determined by subjective ratings and
mechanical sensitivity threshold before and after a standard histamine-dependent itch model on forearms. Itch and pain intensities
were rated on visual and numerical rating scales, respectively. Dispersion of itch was drawn on arm charts. Presence and area of
alloknesis and hyperknesis were determined. Group comparisons were performed in SPSS with a significant level of 0.05.
Descriptive statistic was used for questionnaire’s analysis.
Results: Patients (n=20; 68.10±7.91 y, F/M ratio: 8/12) and controls (n=20; 67.35±7.65 y, F/M ratio: 8/12) were examined. PD
patients rated less physical and emotional descriptors, except for the stinging (P=0.028). No difference was found between the groups
in histamine-provoked itch intensity (P=0.799) or the itchy area. A significantly larger area of hyperknesis was found in PD (P=0.011),
but not for the area of alloknesis (P=0.221). Sex-related responses yielded only a tendency toward higher responses in female patients.
Discussion: PDdoes not seem to influence perception of itch, neither spontaneous nor evoked itch, except for hyperknesis area, which
was found significantly larger in PD patients following the application of histamine. This finding proposes a potential alteration in central
processing of itch that needs further investigation and whether and how it is affected by, for example, PD pathogenesis.
Keywords: Itch, Parkinson disease, Histamine, Quantitative sensory testing, Alloknesis, Hyperknesis
Parkinson disease (PD) is one of the most common neurodegenera-
tive disorders,most frequently affecting individuals over 65 years[1,2],
and it is characterized by motor symptoms, such as bradykinesia,
resting tremor, rigidity, and postural instability, which are linked to
loss of dopamine[3,4]. Nonmotor symptoms (NMS) are also present
such as olfactory dysfunction, sleep problems, constipation, depres-
sion, and pain[5,6]. These symptoms often precede motor
symptoms[7] and might serve as a useful tool for early diagnosis.
Pain is one of the most studied sensory alterations that affects from
30%–95%of PD patients[8,9]. It remains to be elucidated, but loss of
dopamine and dysfunction of the basal ganglia have been linked to
pain in PD[6,8,10,11]. Allodynia and hyperalgesia are also present in
PD[12] and are proposed as features of hypersensitivity within the
central nervous system (CNS). Only a few studies have used
quantitative sensory testing in PD. A lower threshold in response to
the cold pressor test and a lower pressure pain threshold have been
found in PD patients[13]. Sung et al[14] have also found a reduced
pain threshold and an increased pain sensitivity in PD patients.
Andersen et al[15] found a significant difference in PD patients
compared with controls in response to brush and pinprick stimuli
on the forearms and lower back. Considering the literature about
pain and PD, and the fact that itch and pain partially share sensory
pathways[16–20], it is not unexpected to speculate that presence and
sensation of itchmight also be different in PD patients. Itch, similar
to pain, can pose a negative impact on quality of life[21], in parti-
cular, in the aged population, who may also have PD. Generally,
dermatological conditions that can accompany itch are present in
PD[22]. Skin disorders and senile pruritus are common in the elderly
population[21,23]; hence, it can be difficult to distinguish a neuro-
logical etiology from a dermatological one (eg, seborrheic derma-
titis, melanoma, and rosacea[22]), which can further complicate
investigation of itch in PD.
The phenomenon of itch, however, has not been studied in PD.
Therefore, the purpose of this study was to determine if sponta-
neous itch was in fact present in PD patients without evidence of a
dermatological condition. It was hypothesized that PD patients
would present a different occurrence and pattern of general itch
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compared with controls. We also hypothesized that a standard
experimental itch model could provoke itch sensation in both PD
patients and controls, but potentially with different character-
istics. Experimental itch models[24,25], histamine-dependent and
histamine-independent[26], have been developed and used in the
literature for different purposes, such as understanding itch
mechanisms and responsiveness to antipruritic drugs[27,28]. We
applied 1% histamine model to assess the intensity of the pro-
voked itch and to quantify sensory alterations[29]. We hypothe-
sized that PD patients would present a different histamine-evoked
response in terms of itch intensity, size of the itchy area, and
manifestations of central sensitization (alloknesis and hyperkn-
esis) compared with non-PD controls.
Methods
An experimental, parallel-group, open study was performed on
PD patients and their best matched controls [in sex and age ( ± 5
y)]. The subjects participated in one experimental session lasting
~75 minutes. The study protocol was approved by the North
Denmark Region Committee on Health Research Ethics
(N-20180079) and conducted according to the Declaration of
Helsinki, 2013 and Good Clinical Practice (GCP) guidelines. The
study was conducted in 2019 at the Neurology Department,
Aalborg University Hospital, Denmark.
Subjects
Idiopathic PD patients were recruited in collaboration with physi-
cians affiliated at theDepartment ofNeurology, AalborgUniversity
Hospital, Denmark. Best matched controls were recruited through
public notices and online advertisement in the Facebook. Subjects,
who showed interest in participating, received written information
about the study and had the opportunity to ask questions before
committing to participate. Before testing, written informed consent
was obtained from all participants. Thereafter, all participants were
screened for inclusion and exclusion criteria. Only control group
participants were compensated for the time of their participation,
which was approved by the ethics committee.
All included PD patients were within the age range of
50–85 years, diagnosed with idiopathic PDwithin 2–10 years, had
an acceptable cognitive function [Mini Mental State Examination
(MMSE) >24], Caucasian, and could understand and speak
Danish. PD patients were excluded if they suffered from other
peripheral or CNS disorders, musculoskeletal or psychological
conditions; liver or renal conditions; diabetes; any present or pre-
vious dermatological or allergic disorders; addicted to drugs like
cannabis, opioids or other drugs; had consumed alcohol for the last
24 hours; used medication with impact on the immune system or
pain for the last 24 hours; had tattoo, scare, wound at the volar
side of the arm; and if lacked the ability to cooperate.
MMSEwas used as a screening tool to investigate the cognitive
state of the participants. This was performed to ensure that the
participants understood the experimental procedure for the
study. The MMSE was firstly introduced by Folstein et al[30] as a
shortened and simplified version of the cognitive mental status
examination. It is possible to achieve a total of 30 points in the
MMSE, and a score of 23 or less has generally been accepted as an
indicator of cognitive impairment[31].
The controls were matched in terms of sex and age ( ± 5 y) with
the PD group. Otherwise, the inclusion criteria were similar to PD
patients, with the exception of the PD diagnosis. Regarding the
exclusion criteria, the best matched controls were excluded if they
suffered from any peripheral or CNS disease, musculoskeletal or
psychological conditions, and otherwise for the same reasons as
PD patients.
Experimental procedure
The experimental procedure is depicted in Figure 1.
The first part consisted of a screening session to check the
inclusion-exclusion criteria and to obtain descriptive data of the
study population. In addition, MMSE scores and the history of
itch perception were recorded.
A circle with a diameter of 8 cm was drawn in the middle of
the volar surface of the dominant forearm for the mechanical
sensitivity threshold (MST). The dominant forearm was defined
as the arm of the most PD-affected side in patients, whereas in
the best matched control group the side was the actual dominant
forearm.
For the baseline assessment of sensory perception, in the middle
of themarked area, a light touch test was donewith a cotton swab,
followed by pinprick stimulation to determine the MST.
Afterwards, histamine was applied to the middle of the marked
area to provoke itch. The participants were asked to rate their itch
on a visual analog scale (VAS) and their pain on a numerical
rating scale (NRS) every 30 seconds. The value 0 indicates “no
itch/no pain” and the value 10 indicates “the worst imaginable
itch/pain.”The test was completed when the itch had disappeared
or after 15 minutes had passed.
Thereafter, the areas of alloknesis, hyperknesis, and perceived
itch were assessed. While the alloknesis and hyperknesis were
mapped using, respectively, cotton swabs and pinpricks, the dis-
persion of perceived itch was drawn on an arm chart. The itch
dispersion was an attempt toward finding the graphical pattern of
itch presentation. The idea was formed based on a recent study in
pain[32], which has proposed that this method can help in screening
of pain in patients.
During the sensory testing, the participants were instructed to
look away or close their eyes. All procedures were performed by
the study investigators following predefined standard operating
procedures. All data were recorded in the Case Report Forms
(CRFs) and organized in Excel sheets for further statistical
analysis.
Tests
Questionnaire to examine the history of itch perception
With the custom-made questionnaire, the participant’s experi-
ence with spontaneous itch was investigated. This included
identification of perception, history, and patterns of itch. The
questionnaire was developed in Danish, tested in a pilot trial, and
approved by the ethics committee. It was made with inspiration
obtained from two validated questionnaires, “Eppendorf Itch
Questionnaire”[32] and “McGill Pain Questionnaire”[33]. The
custom-made questionnaire consisted of two parts. Part A con-
sisted of 70 different descriptors and was filled out by each sub-
ject. The first 35 descriptors described the physical sensation of
itch, whereas the last 35 descriptors described the emotional
sensation of itch. The different descriptors were scored on a scale
of 0–4; 0 being “not true” and 4 being “describes my sensation of
itch exactly.” Part B consisted of different questions about the
Sondrup et al. Itch (2021) 6:e49 Itch
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location and duration of itch, and explored strategies to avoid or
relieve itch. In addition, the location of itch was marked on a full
body drawing. Part B was filled out by the investigator entering
the answers from the participants. The questionnaire overall was
used to compare the perception of itch in the 2 groups and to
determine if a general difference in the feeling of itch existed
between the PD patients and the controls before the experimental
procedure.
Light touch test
At baseline, a light touch test was performed using cotton swabs
(Wood Hospital Applicators, Mediq, Brøndby, Denmark) to test
the responsiveness to the light touch, which is usually used to test
the perception of tactile touch input[34]. The light touch test was
performed with the purpose of testing if any sensory disturbances
were present within the test area and if the touch of the cotton
swab could be felt as normal or absence of tactile sensation, itch,
or pain. Please note that this test was to dab the skin rather than
stroking it. In cases of feeling itch or pain, the participants had to
rate the itch on the VAS (0–10) and the pain on the NRS (0–10).
0 indicated “no itch/pain,” and 10 was “the worst imaginable
itch/pain.” These scales helped subjects to stay clear for the rating
of the 2 different sensations of pain and itch and to avoid con-
fusion. The light touch test was repeated 3 times and averages of
VAS and NRS scores were recorded.
Assessment of MST
MST is used to determine the threshold of sensitivity to
mechanical stimuli such as pinpricks[32] that activate the Aδ-fiber
and C-fiber[35]. In this study, the purpose of the MST was to
determine the individual’s threshold of sensitivity and the
occurrence of sensory abnormalities. This test is usually used to
identify hyperalgesia or hyperknesis[29]. Seven different weighted
pinprick stimulators (MRS systems GmbH, Heidelberg,
Germany) were used. The pinpricks (blunt needles with a fixed
stimulation intensity of 8, 16, 32, 64, 128, 256, and 512mN)
were applied perpendicular to the skin in ascending-descending
order, followed by descending-ascending order, based on a
standard procedure[32]. This procedure was repeated 3 times and
the MST was calculated using the weight of the pinprick the first
time where the subject detected a difference in the sensory
perception.
After each prick, the subject was asked to rate the itch on the
VAS, rate the pain on NRS, and indicate if there was a noticeable
change in sensory perception between the pricks. The averages
for itch and pain were also calculated.
Application of histamine
To investigate the responsiveness to a standard evoked itch
between PD patients and controls, the histamine-dependent itch
model was used by the application of histamine on the disinfected
and dried volar surface of the dominant forearm. If the subjects
Figure 1. Overview of the experimental procedure, including tests, order of tests, and timeline. MMSE indicates Mini Mental State Examination; MST, mechanical
sensitivity threshold; NRS, numerical rating scale; VAS, visual analog scale.
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had any pain or itch sensation before application of histamine, it
was rated on the related scales and recorded.
One drop of 1% histamine dihydrochloride (ALK-Abelló
Nordic A/S, Hørsholm, Denmark) was placed on the test area, and
a finger pricker (Softlance “Fingerprikker”: Mylife, Bionime
Corporation, Taichung City, Taiwan) using 0.32mm lancets (Soft
Fine Colour, REF 110, Klinion, Medecon B.V., The Netherlands)
was used to permit histamine reaching into the epidermis. Each
subject rated the evoked itch on a VAS and pain intensity on an
NRS, every 30 seconds. The average VAS score of the itch and the
average NRS score of pain were calculated and used for further
statistical analysis. The experiment ended when the histamine-
induced itch disappeared, or 15 minutes after application of
histamine, or when the last 3 readings were below 1 following ≥3
subsequent rating.
Mapping and assessment of dysesthesia
Itch dysesthesia is defined as an uncomfortable abnormal sensa-
tion, which induces itch by light stimuli and is described in terms
of alloknesis and hyperknesis[29]. These areas together with the
perceived itchy area were mapped.
Alloknesis was assessed with brushing skin lightly by a cotton
swab starting at one of the outer marks of the octagon (4 cm from
the histamine application site) and moving in intervals of 0.5 cm
toward the application site. This was repeated for all the outer
marks, and the area was mapped by 8 horizontally arranged
paths. The subject was instructed to report when the application
of the cotton swab changed to a feeling of itch. The site of the
change in perception was marked, the identified points on each
path were connected and scanned, and the area (cm2) was
quantified using Vistametrix (Version 1.38, Skillcrest, Tucson).
Hyperknesis was determined with the individual MST. This
was done as described above on the octagon and the subject was
instructed to report when the prick sensation was changed to
noticeably more itch or other sensory feeling. Areas of hyperkn-
esis were then quantified by tracing and measurement of the area
with the aid of Vistametrix.
Finally, the subjects were asked to draw the area of their per-
ceived itch on an arm chart. The drawings from the PD patient
group and the control group were superimposed separately to
investigate the pattern of dispersion following histamine provo-
cation. The areas were then digitized and quantified (cm2) using
Vistametrix.
Data analysis
In this study, flowcharts were created using Lucidchart (Lucid
Software Inc., South Jordan, Utah). Microsoft Excel [Microsoft
Excel for office 365 MSO (16.0.12130.20232)] was used to
organize data, and GraphPad Prism (version 8.1.0 2018) was
used to construct graphs to visualize the data. Vistametrix
(Version 1.38, Skillcrest, Tucson) was used to quantify the area
(cm2) of alloknesis, hyperknesis, and dispersion of itch on the arm
chart. Data are presented as arithmetic means ± SD or as median
and the interquartile range (Q1Q3).
G*Power (Version 3.1.9.2, Franz Faul, Kiel University,
Germany) was used to calculate the power. Initial sample size
determination in the study protocol was based on a published
study[15] conducted to identify pain and other sensory dis-
turbances, with 80% power that yielded 40 participants.
Statistical Package for Social Sciences Software (SPSS) (IBM
SPSS, version 26, Armnok, New York) was used to determine if
the data were normally distributed using the Shapiro-Wilk. On
the basis of this, parametric or nonparametric ways for data
presentation and tests for comparisons were followed. All sta-
tistical tests were considered significant at a P-value ≤0.05.
Questionnaires regarding the history of perceived itch were
analyzed. The most frequently used physical, sensory, and emo-
tional descriptors were selected, and the mean and SD were cal-
culated. Bar charts were constructed to illustrate the frequency
(%) and the mean ratings of the most used sensory and emotional
descriptors. The ratings of these descriptors were compared using
Mann-Whitney U tests, for non-normally distributed data, and
2-samples independent t test, for normally distributed data. The
Levene test was completed to meet the assumption of homo-
geneity of variances for the 2-sample t test. Levene test results
presented homogeneity of variances where a P-value above 0.05
was found.
The locations of itch from the body charts were superimposed
on transparent papers to investigate if a pattern was observed.
Finally, the intensity of itch was rated on a visual scale, whichwas
converted to a scale from 0 to 10 to investigate the different itch
intensities in the 2 groups. Mann-Whitney U test was used to
compare these itch intensities to determine if a significant differ-
ence was observed.
All data from the different sensory tests (light touch test,
individual MST, histamine response) were used to investigate if a
difference between the 2 groups was present. To compare the
VAS for itch and NRS for pain, respectively, 2-sample indepen-
dent t-tests were performed on normally distributed data, and
Mann-Whitney U tests were performed on non-normally dis-
tributed data. Area under the curve (AUC) was calculated for the
VAS-time curve of histamine-provoked itch and the NRS-time
curve of histamine-provoked pain for both groups. AUC was
used to identify an overall sensation of itch and pain, considering
both intensity and duration of these sensations to provide further
information in addition to the peak intensity and the duration,
separately.
Moreover, Spearman correlation analysis was performed for
itch intensity and, respectively, to find out if disease duration and
age could be correlated with this. The rationale behind the test
was that it has been reported that age and neurodegenerative
diseases can alter the 5 senses[36]. Moreover, 2-sample indepen-
dent t tests were used to investigate if any difference in histamine-
provoked itch intensity was observed between male and female
participants, based on the literature pointing to the potential of
sex-based responses in itch[37,38].
The areas of alloknesis, hyperknesis, and the dispersion of itch
on the arm chart were quantified in Vistametrix. Mann-Whitney
U test was used for each area to investigate if any difference was
observed between the PD patients and controls. The dispersion of




Eighty PD patients and 38 controls were recruited for participa-
tion in the study. Eighteen PD patients and 5 controls declined to
participate, and 42 PD patients and 13 controls were excluded as
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they did not meet the criteria. Therefore, the study population
consisted of 20 PD patients and 20 best matched controls with
8 females and 12 males in each group. The mean age ± SD was
68.10 ± 7.91 years in the PD group and 67.35 ± 7.65 years in the
control group (Fig. 2). An independent 2-sample t test found no
significant difference in age between the 2 groups (P=0.792).
Table 1 shows the demographic and clinical characteristics of
the PD patients and the control group. The included PD patients
had on average a disease duration with a PD of 6.33±2.55 years
and they all were treated with PD medications (Levodopa pre-
paration: Madopar, Madopar Quick, Stalevo, Levo-dopa,
Sinemet. Dopamine agonist: Ropinirol, Oprymea, Sifrol, Sifrol
depot. Monoamine Oxidase B inhibitor: Rasagilin). One PD
patient was on dopamine agonist monotherapy. Eight PD patients
only received levodopa treatment, while the remaining 11 received
levodopa treatment in combination with other PD medications
(Table 1). In addition, the interval between intake of medication
was different among the patients; 1 PD patient only took medi-
cation once a day, while others used it up to 8 times per day.
Finally, the subjects were asked if they had or had had any pro-
blems with itch throughout life. In all, 40% of the PD patients and
35% of the controls reported previous or present problems
with itch.
Questionnaire
Previous or present experiences with itch
All subjects, regardless of past or present itch problems, were
asked to fill out a Danish questionnaire.
The questionnaire was used to investigate, which physical,
sensory, and emotional descriptors the participants used to
describe the sensation of itch. The subjects who did not have any
problems with the itch were told to think about the feeling of a
mosquito-bite if facing difficulties to answer the questions. The
frequency of the most used physical and emotional sensory
descriptors is summarized in Table 2.
The participants also indicated general and major locations
of their itch experience in the past. The body charts were
superimposed and are presented in Figure 3. In general, espe-
cially, the shin was a frequent itch location, but the chest, back,
and the scalp were also common places for the sensation of itch
in the study population. No clear pattern was observed in
either group.
Age-based responses
The literature presents that the elderly population are prone to
itch associated with age-related changes that occur in the skin,
some comorbidities and medication use, and psychological
conditions[39,40]. To investigate if any difference existed in the
spontaneous intensity of itch, reported based on the age, the
Figure 2. Flowchart of the recruitment of study participants, which consisted of 2 groups; PD patients and best matched controls. When all inclusion and exclusion
criteria were fulfilled, 20 PD patients and 20 controls were included in the study. Age is indicated in years. CNS indicates central nervous system; PD, Parkinson
disease.
Table 1
Demographic and clinical characteristics of PD patients and
controls.
PD Patients (n= 20) Controls (n= 20)
Age (y) 68.10± 7.91 (54–81) 67.35± 7.65 (52–77)
Sex (female/male) 8/12 8/12
Dominant arm (right/left) 14/6 19/1
MMSE 29.40± 0.99 (26–30) 29.70± 0.66 (28–30)
Disease duration (y) 6.33± 2.55 (2–10) —
Age of onset (y) 61.78± 9.03 (45–79) —
PD medication
Levodopa (%) 90 —
Dopamine agonist (%) 40 —
MAO-B inhibitor (%) 25 —
Presence of itch (%) 40 30
Note: several PD patients received more than one type of PD medications.
MAO-B indicates monoamine oxidase-B; MMSE, Mini Mental State Examination; PD, Parkinson
disease.
Sondrup et al. Itch (2021) 6:e49 www.itchjournal.com
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median of age for all participants was calculated and the fol-
lowing age ranges were determined; the younger age range was
52–68 y and the older age range was 69–81 y for PD patients and
controls. The Mann-Whitney U test showed no significant dif-
ferences between the PD patients and controls in the lower or the
higher age range. The Mann-Whitney U test was also used for
within-group comparison, which demonstrated no significant
difference between PD patients in different age ranges (P=0.739)
or between the controls (P=0.436).
Sex-based responses
Amixed outcome has been presented in the literature with regard
to sex differences in itch. However, a general finding is that in
chronic pruritus, itch characteristics, for example, itch intensity,
are higher in females[37,38,41]. Our population included both
females (16) and males (24). Therefore, we analyzed data to see if
any sex-related responses existed in 4 groups of PD males, PD
females, control males, and control females. The Kruskal-Wallis
test found no significant difference in scratching between any of
the 4 groups (P=0.826).
The ratings of company distracts as a way to deal with the
sensation of itch were lower in males with PD compared with the
control males. Themedian was 1.0 (1.0–1) for males with PD and
3 (1.5–3.0) for the control males. The opposite was observed
among the female participants; the median was 2.0 (1.0–3.0) for
females with PD and 3.0 (2.0–4.0) for females of the controls.
When comparing males and females in the 2 groups, no differ-
ences were found (Kruskal-Wallis test comparing the 4 groups,
P= 0.826).
The ratings of gives satisfaction in relation to scratching the
itch did not present any significant difference where medians were
compared with the Kruskal-Wallis test (P=0.824). The Kruskal-
Wallis test found no significant difference in the ratings of
scratching decreases itch between any of the 4 groups either
(P= 0.266).
The ratings of the past itch intensity were also investigated in
relation to sex. The median VAS was 3.0 (2.0–5.0) for the males
with PD and 3.5 (1.0–7.0) for the males in the control group. A
lower past itch intensity was observed among the female PD
patients [2.0 (1.0–6.75)] compared with the females in the
control group [5.0 (3.0–6.75)]. Comparing the males and
females in both groups, the females in the control group had the
highest median. However, the Kruskal-Wallis test found no
Table 2
Summary of the itch history questionnaire.
Frequency (%) Mean Ratings± SD
PD C PD C
Sensory descriptors
Pricking 55 55 1.91± 0.94 1.64± 0.81
Give the creeps 40 30 2.75± 0.71 2.67± 1.37
Like sunburn 40 25 2.25± 0.89 1.60± 1.34
Stingning 35 65 1.71± 0.76 2.53± 1.05
More when warm 45 45 2.33± 1.00 2.00± 1.00
Mosquito bite-like 35 45 2.29± 0.75 2.67± 0.87
Itching 50 80 2.90± 1.29 2.56± 1.15
Palpable 50 40 2.20± 0.92 2.00± 0.75
Emotional descriptors
Bothering 80 90 2.38± 1.02 2.06± 1.21
Annoying 65 85 2.08± 0.95 2.41± 1.18
Unpleasant 45 60 2.56± 1.13 2.5± 1.09
Disturbing sleep 20 35 1.25± 0.50 1.71± 0.49
Disturbing in general 30 40 2.50± 1.22 1.78± 0.97
Scratch behavior
Scratching 65 80 2.23± 1.01 2.13± 0.96
Rubbing 35 50 2.29± 0.95 2.20± 0.79
Company distracts 35 45 1.71± 0.95 2.77± 0.97
Gives satisfaction 70 65 2.29± 1.27 2.38± 0.96
Decreases itch 50 45 2.20± 1.14 2.33± 1.12
The frequency in % of the most selected physical sensory descriptors, emotional descriptors, and
descriptors related to scratch behavior of Parkinson disease patients and controls are presented. The
mean ratings (rated from 0 to 4) ± SD of these descriptors are shown.
C indicates controls; PD, Parkinson disease.
Figure 3. A, Body charts illustrating localization of itch in patients with Parkinson disease and (B) in controls.
Sondrup et al. Itch (2021) 6:e49 Itch
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significant difference in itch response between the 4 groups
(P= 0.471).
Mechanical sensitivity
To investigate if the participants had any presence of alloknesis
on their dominant forearm, a light touch test was performed. One
of the PD patients had an average itch sensation of 0.2 ± 0.35 on
the VAS, while another PD patient had a mean pain sensation of
0.67 ± 1.2 on theNRS.None of the controls had any sensations of
itch or pain with the touch of cotton swabs. The Mann-Whitney
U tests found no significant difference between the PD patients
and the controls regarding itch sensation (P= 0.317) and pain
sensation (P= 0.317) in relation to the light touch test.
To investigate the presence of hyperknesis in PD patients and
controls, the individual MST was used on the dominant forearm.
The medianMST in PD patients was 162.09 (122.67–298.67)mN,
while the median of the controls was 165.34 (102.67–234.67)mN.
The Mann-Whitney U test found no significant difference in the
mean MST between PD patients and controls (P=0.543). The
presence of hyperknesis was investigated with itch ratings on a VAS
during the assessment of MST. During the pinprick test, the
occurrence of itchwas observed in 6 (30%) of the PDpatients and in
2 (10%) of the controls. The Mann-Whitney U test found no sig-
nificant difference in hyperknesis between the 2 groups (P=0.126).
In addition, the 2 groups had to rate pain on the NRS during
theMST. The occurrence of pain was observed in 12 (60%) of the
PD patients and in 11 (55%) of the controls. The Mann-Whitney
U test found no significant difference in the rating of pain during
the MST determination between the 2 groups (P=0.455).
Histamine response
The application of histamine was performed on the dominant
forearm. On average, the duration of itch was 8.35 ± 3.89 min-
utes for the PD patients and 8.38 ± 3.56 minutes for the controls.
However, 1 control already felt the itch before the histamine
application, and 2 controls and 1 PD patient did not feel any itch
after the histamine application.
Figure 4A illustrates the itch response in relation to histamine
application over time for PD patients and controls.
Themedian VAS rating of itchwas 1.04 (0.47–1.84) for the PD
group and 1.2 (0.68–1.89) for the controls. The Mann-Whitney
U test found no significant difference between the PD group and
the control group (P=0.799). In addition, AUC was calculated
for the VAS-time curve of the PD group (AUC= 881.7 mean itch
VAS×minutes) and the control group (AUC= 870.15 mean itch
VAS ×minutes). However, no significant difference was found
between the 2 groups either.
The Mann-Whitney U test was also performed on peak of itch
intensity, and no significant difference was evident between the
groups (P=0.88). The time to reach to the peak itch intensity was
also determined,whichwas 150 (60–240) seconds for the PDpatients
and 165 (150–210) seconds for the controls. The Mann-Whitney U
test showed no significant difference in the time to reach to the peak
itch intensity between PD patients and controls (P=0.547).
Furthermore, during the application of histamine, the 2 groups
were asked to rate pain on anNRS. Figure 4B illustrates the mean
rating of histamine-generated pain in PD patients (red) and in
controls (blue).
The Mann-Whitney U test found no significance difference in
the mean of pain rating between the 2 groups (P=0.057).
Moreover, the AUC of the NRS-time curve was 275.7 mean
pain NRS×minutes in the PD group and 109.5 mean pain
NRS×minutes in the control group, but no difference was
found.
Age-based responses
To investigate if any difference existed in the responsiveness to
histamine between PD patients and controls as a function of age,
younger age range (52–68 y, N=10) and older age range (69–81
y, N= 10) for PD patients and controls were compared. A
2-sample t test demonstrated no significant differences between
the PD patients and controls in the lower age range (P=0.708).
Similarly, no significant difference between PD patients and
controls for the higher age range was obtained (P=0.939). To
investigate differences in the responsiveness to histamine between
the different age ranges within each group, an independent t test
demonstrated no significant differences between the age ranges in
PD (P= 0.749). Likewise, an independent t test demonstrated no

















































Figure 4. A, VAS-time curve of histamine-provoked itch for PD patients (red)
and controls (blue). The itch intensity was rated on a VAS from 0 to 10 every 30
seconds until the itch subsided or for 15 minutes. No significant overall differ-
ence was found in the sensation of histamine-provoked itch between the 2
groups (P= 0.921). B, NRS-time curve of the histamine-provoked pain for the
PD patients (red) and controls (C) (blue). The pain intensity was rated on an NRS
from 0 to 10 every 30 seconds. C indicates control; NRS, numerical rating
scale; PD, Parkinson disease; VAS, visual analog scale.
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Sex-based responses
The histamine-evoked itch intensity is presented in Figure 5A for
males and females in PD and control groups. The 1-way analysis
of variance found no significant difference in itch response
between the 4 groups (P= 0.482).
Regarding pain sensation, the Kruskal-Wallis test found no
significant difference in pain response between any of the 4
groups (P= 0.094) (Fig. 5B).
Age and itch responses
There was a negligible correlation between age and histamine-induced
itch intensity. Spearman correlation coefficient rs was 0.028, when it
was tested for the mean of the itch intensity. The correlation was not
statistically significant (P=0.865). Pearson correlation analysis of the
peak of itch intensity also showed no significant correlation.
Disease duration and itch responses
There was a negligible correlation between disease duration and
histamine-induced itch response in PD patients, as the Pearson
correlation was 0.076 (P=0.749).
Areas of alloknesis and hyperknesis following histamine
provocation
The presence and patterns of alloknesis and hyperknesis areas on
the dominant forearm were investigated after the histamine-
provoked itch had returned to 0. The areas were determined and
subsequently quantified (cm2) by Vistametrix. The box plot in
Figure 6A demonstrates the areas of alloknesis and hyperknesis
(cm2) observed in PD and the control groups. The median area of





















Figure 5. A, Itch intensity of themale (light blue) and female (purple) participants
of the PD group and the control (C) group. The histamine-provoked itch
intensity was rated on a VAS from 0 to 10 every 30 seconds. No significant
differencewas found between the groups. B, Box plots illustrating pain intensity
for the male (light blue) and female (purple) participants of the PD group and the
control (C) group. The histamine-provoked pain intensity was rated on an NRS
from 0 to 10 every 30 seconds. No significant difference was found between
any of the 4 groups. C indicates control; NRS, numeric rating scale, PD,
Parkinson disease; VAS, visual analog scale.
Figure 6. A, Box plot illustrating the median area of alloknesis in cm2 in the PD
group (red) and controls (blue). No significant difference was observed in the
area of alloknesis (P=0.221). B, Box plot illustrating the median area of
hyperknesis in cm2 in the PD group and the control group. A significant dif-
ference was observed in the area of hyperknesis (P=0.011). C indicates
control; PD, Parkinson disease. *P≤0.05.
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(0.74–2.2) cm2 in the control group (Fig. 6A). The Mann-
Whitney U test found no significant difference between the 2
groups (P= 0.221).
The median of the area of hyperknesis was 7.77 (2–17.15) cm2
in PD patients and 1.54 (0.74–5.24) cm2 (Fig. 6B). The Mann-
Whitney U test found a significant difference between the 2
groups (P=0.011). This indicates that the PD patients had a
significantly larger area of hyperknesis after the histamine
response compared with the control group.
Itch dispersion after histamine application
The dispersion of itch following the application of histamine was
traced on the arm charts and the areas (cm2) were quantified by
Vistametrix. Figure 7 illustrates the dispersion of itch in PD
patients and controls. The dominant arm was defined differently
in the two groups, as it was the most affected side of PD patients,
which was used for the experiment. This explains the
higher number of drawings on the left arm chart in the PD
group compared with the control group. Figure 7 shows that
the dispersion of itch after histamine application was more scat-
tered and further away from the region of the histamine prick test
in the PD group compared with the control group. The median
area was 3.84 (0.92–6.88) cm2 for the PD patients and 1.32
(0.28–5.75) cm2 for the controls, and the Mann-Whitney
U test found no significant difference between the 2 groups
(P= 0.185).
Discussion
This study was the first to investigate patterns and characteristics
of itch in PD. Themain finding was a larger area of hyperknesis in
response to histamine-provocation test in PD patients compared
with controls.
Experiences of itch
The most frequent sensory descriptors chosen were different
between the two groups, but with no significant difference.
Majority of controls selected the sensory descriptors “itching”
and “stinging,” while PD patients selected a wider and more
diverse range of words. The PD patients might have found it
easier to describe the itch and relate to descriptors such as
“palpable” and “give the creeps.” The most frequent emotional
descriptors were rated with a higher severity by the controls
compared with the PD patients, but no significant difference was
found. Emotional descriptors such as “bothering” and “annoy-
ing”were the most scored emotional descriptors for both groups.
There was also no difference between the groups in the locali-
zation of past itch experience. Larger, population-based studies
are required to delineate general perception of itch descriptors
and localization in patients with PD.
Looking at data related to scratch behaviors, the two groups
seemed equal in how they describe their behavior toward relief of
itching. The most frequently observed method to deal with itch-
ing was scratching in both the PD group and the control group.
Moreover, 70% of PD patients and 65% of controls stated that
scratching their itch resulted in a satisfying feeling. This shows
that both PD and control subjects act similarly in terms of scratch
when feeling itch. The feeling of satisfaction correlates with the
findings of Papoiu et al[27] that the act of scratching an itch is
rewarding and gives a feeling of pleasure. Furthermore, we know
that cognitive attention and/or distractions have a great influence
on pain[42,43] perception and thereby reduce the intensity.
Distraction might influence itch similar to pain, and that might be
Figure 7. Arm charts illustrating localization of itch dispersion in (A) Parkinson disease (PD) patients (red) and (B) controls (C) (blue). PD: 3.84 (0.92-6.88) cm2, C:
1.32 (0.28-5.75) cm2. Note that the drawing outside the arm chart refers to expansion to the other side of the arm, where one patient sensed and reported it.
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based on the involvement of some feelings or emotions. However,
van Houtum et al[44] have reported that chronic illness could
affect the energy and presence in social context, where basic and
social problems in daily life were observed in one-third of the
1713 patients with chronic diseases. This might also influence PD
patients. The scratch behavior was not different between male
and female participants. In a former study[38], females and males,
however exhibited differences in their itch perception as reflected
on higher itch intensities and desire to scratch in females.
However, we cannot directly compare our data with Ständer
et al[38], who focused on patients with chronic pruritus under
different age and disease conditions.
Of our PD patients, 40% reported previous problems with
itch, which can indicate that itch is a sensory modality that affects
some PD patients. However, 35% of the controls also reported
previous problems with the itch. This opens a new proposal that
itch sensations can be explained by other factors such as vitamin
deficiency or being of old age, as previous studies have found
a high occurrence of pruritus conditions in the elderly
population[23,45,46]. To test this, we sub-divided participants into
2 age groups: younger age group (52–68 y) and older age group
(69-81 y). However, comparison of these 2 groups did not show
any significant difference.
Mechanical sensitivity
This study found no baseline presence of alloknesis or a difference
of developed alloknesis following the histamine-evoked itch
between the 2 groups of PD and controls. The presence of
alloknesis in PD patients has not previously been investigated;
therefore, there is not a base for comparison, and the potential
mechanism cannot be ruled out with the method and measure-
ments of this study. However, Andersen et al[15] found dynamic
mechanical allodynia in 58.33% of PD patients with a brush test.
We did not find hyperknesis at baseline, but the PD patients
had a significantly larger area of hyperknesis following the his-
tamine-evoked itch compared with the controls. Hyperknesis and
hyperalgesia are suspected to share somewhat similar
mechanisms—involvement of the central sensitization. Hyperse-
nsitivity to pain has been reported in PD and a meta-analysis has
provided evidence for the presence of hyperalgesia in PD
patients[47]. This suggests that in PD patients a state of sensiti-
zation is present that might also explain a larger area of
hyperknesis following the histamine-evoked itch. High con-
centrations of α-synuclein have also been observed in the skin of
PD patients[22], which can explain alterations the function of
sensory fibers. However,Wang et al[48] did not find evidence of α-
synuclein accumulation in the sensory fibers in the skin of PD
patients. Deposition of α-synuclein in the CNS is, however, a
common finding in PD[49] and can influence the alterations in
centrally mediated sensory information.
A potential effect of medication must also be considered in
sensory responses tested in this study. It has been demonstrated
that pain thresholds are lower in patients without dopaminergic
drugs, but return to the normal level with levodopa treat-
ment[11,50]. Of our PD patients, 90% were on levodopa and
besides alterations that this drug can cause in sensory perception
related to pain, it has been reported that levodopa can cause
itching as a side effect. The effect of PD on different sensory fibers
and the outcome with and without medication need further
investigation.
Histamine-induced itch intensity
No significant difference was observed between the temporal
profile of the histamine-induced itch between PD patients and
controls. Evoked itch intensity, in terms of peak, or overall itch
(AUC under itch intensity-time curve) did not yield any significant
difference between PD and controls. Histamine-induced itch
sensation disappears usually after 8–15 minutes[51], and we also
observed that on average the itch disappeared in both groups
within this time range.
Studies have reported that the prevalence of pruritus increases
with age and can be partially attributed to a decline in normal
physiological status of the skin[52–54]. However, this study found
no correlation between age and histamine-induced itch intensity.
A higher pain, however, was observed throughout the entire
experiment in PD patients compared with controls, which is in
line with previous reports[13,15,55,56]. Several mechanisms have
been proposed to underlie the effects seen as sensory alterations
related to pain in PD. For example, mitochondrial dysfunction in
dopaminergic neurons in PD has been proposed to lead to
hyperactivity of the nociceptors[57]. Another theory is that
decreased levels of dopamine in PD might result in a lower pain
threshold[9]. However, inconsistent results are present in the lit-
erature of pain in PD patients with and without levodopa
treatment.
Only a few studies have explored sex differences in relation to
pruritus[37,38]. Ständer et al[38] investigated 1037 patients (469
males; 568 females) with chronic pruritus and concluded that
females more often reported occurrence of localized itch attacks,
with stinging, warmth and painful qualities compared with the
males with chronic pruritus. A study by Stumpf et al[58] (278
males; 341 females) has shown that females were more anxious
than males, and that anxiety scores in females were related to the
intensity of pruritus. Multiple explanations could justify the dif-
ference in itch sensations between males and females. We did not
find any sex-related response, but a larger cohort is required to
investigate possible sex-related differences.
Dispersion of itch in response to histamine-induced itch
model
When using the histamine-evoked itch model, the sensation and
dispersion of itch are expected to be centered around the
application site[51], which was also the case in this study. The
dispersion of itch was traced on the arm charts after the hista-
mine-induced itch had disappeared. No significant difference was
found between PD patients and controls; but the dispersion of
itch was more scattered and away from the center of the hista-
mine application area in PD patients compared with controls.
Perhaps, neurodegeneration of unmyelinated fibers in PD patients
could affect the itch-transmitting C-fibers[59], which could
explain the difference in itch dispersion. However, lack of sig-
nificant difference in finding requires future studies with appli-
cation of other methods such as nerve recording or brain imaging
techniques, for example, functional magnetic resonance (fMRI)
could be a useful tool to detect the centers that are activated in
the brain. We still do not know if a phenomenon similar to the
referred pain[60] may occur in relation to itch, that is “referred
itch.” The scattered itch dispersion in PD patients might be
explained by the appearance of referred itch potentially medi-
cated by the central sensitization.
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This pilot study is not without limitations. Other itch provo-
cation tests (eg, nonhistaminergic provocations) could be tested
with application of other methods in addition to psychophysical
measurements to shed light on the mechanisms underlying sen-
sory alterations. It has been proposed that histamine activates
2 populations of afferent fibers, one that mediates itch and
alloknesis and the other that activates pain pathways and gives an
antipruritic effect to itch and its associated dysesthesia[61]. How
PD mechanisms can influence sensory alterations in response to
itch needs further basic research[62] in line with clinical studies.
Conclusion
This study investigated the patterns and characteristics of sensory
abnormalities with a focus on itch in PD patients compared with
their matched controls. There was no significant difference in
spontaneous or evoked itch parameters between the 2 groups,
except the presence of significantly larger areas of hyperknesis in
response to the histamine-induced itch model in PD patients. This
finding proposes a potential alteration in central processing of
itch that needs further investigation and whether and how it is
affected by, for example, PD pathogenesis.
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